Kura Oncology Finds $60M For Cancer Treatments

La Jolla-based Kura Oncology, a biopharmaceuticals startup focusing on treatments for solid tumors and blood cancers, has raised $60M in a private placement. The company said the funding came from EcoR1 Capital, along with Fidelity Management & Research Company, ARCH Venture Partners, Boxer Capital of Tavistock Life Sciences, Partner Fund Management, Nextech Invest, and others. In addition to the funding, the company said it has licensed technology from Janssen Pharmaceutica, and has entered into a reverse merger with Zeta Acquisition Corp II, a publicly traded company ("shell"), making it a public on the OTC markets.